Executive profile: Genzyme's CEO on dark times, transition and the long view
This article was originally published in Scrip
Executive Summary
David Meeker, CEO of Sanofi company Genzyme, recently found himself hustling back to Genzyme's Kendall Square offices from a nearby meeting to talk to Scrip's editor Eleanor Malone about the challenges and opportunities he has encountered in his varied career. In the first of a two-part series, he discusses his experiences in the company that he joined in 1994, and expounds upon issues faced by the industry as a whole.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.